Open AccessIsocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience
Author(s) -
Homan Mohammadi,
Kevin Shiue,
G. Daniel Grass,
Vivek Verma,
Kay Engellandt,
Dirk Daubner,
Gabriele Schackert,
Mercia Gondim,
Dibson D. Gondim,
Alexander O. Vortmeyer,
Aaron Kamer,
William Jin,
Timothy J. Robinson,
Gordon A. Watson,
Hsiang-Hsuan Michael Yu,
Tim Lautenschlaeger
Publication year - 2019
Publication title -
neuro-oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 14
eISSN - 2054-2585
pISSN - 2054-2577
DOI - 10.1093/nop/npz050
Subject(s) - idh1 , isocitrate dehydrogenase , medicine , temozolomide , hazard ratio , glioblastoma , nuclear medicine , oncology , chemotherapy , cancer research , confidence interval , mutant , enzyme , biology , biochemistry , gene
Pseudoprogression (psPD) represents false radiologic evidence of tumor progression and is observed in some glioblastoma (GBM) patients after postoperative chemoradiation (CRT) with temozolomide (TMZ). The ambiguity of the psPD diagnosis confounds identification of true progression and may lead to unnecessary interventions. The association between psPD and isocitrate dehydrogenase 1 ( IDH1 ) mutational (mut) status is understudied, and its incidence may alter clinical decision making.